Rigel Pharma shares are trading higher. The company announced an exclusive, global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU, oral PROteolysis TArgeting Chimera.

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Comments

No comments yet. Be the first!